相关实验视频

Updated: Jun 26, 2025

HOX Loci Focused CRISPR/sgRNA Library Screening Identifying Critical CTCF Boundaries

HOX Loci Focused CRISPR/sgRNA Library Screening Identifying Critical CTCF Boundaries

Published on: March 31, 2019

使用HOXA9/DNA结合抑制剂诱导AML细胞分化,作为对HOXA9-依赖AML的潜在治疗选择

Mélanie Lambert^1,2, Samy Jambon¹, Mohamed A Bouhlel¹

¹Univ. Lille, CNRS, Inserm, CHU Lille, IRCL, UMR9020-U1277-Canther-Cancer Heterogeneity, Plasticity and Resistance to Therapies Lille France.

|May 8, 2024

概括

新的DNA结合竞争对手DB1055和DB818通过向HOXA9转录因子来治疗急性髓性白血病 (AML),可能克服化学抵抗并改善患者的治疗结果.

科学领域:

血液学血液学血液学
分子生物学分子生物学
癌症研究癌症研究

背景情况:

急性髓性白血病 (AML) 的治疗严重依赖于化疗,由于复发和化疗抵抗,生存率不佳.
在70%的AML病例中存在的HOXA9过度表达与预后不佳和治疗失败有关.
针对HOXA9,这是AML的关键驱动力,仍然是一个重大的临床挑战.

研究的目的:

为了评估新型HOXA9/DNA结合竞争者的抗白血病作用,DB1055和DB818.
为了比较DB1055和DB818对HOXA9敲击和标准化疗 (cytarabine) 的疗效.
研究抑制HOXA9-DNA相互作用的潜力,作为AML的治疗策略.

主要方法:

使用人类AML细胞模型和患者衍生AML爆发的体外研究.
使用人类THP-1 AML小鼠模型和NSG小鼠患者衍生异种移植的体内研究.
细胞生长,死亡,分化,转录基因变化和白血病负担的评估.

主要成果:

DB1055和DB818在体外显示出显著的抗白血病作用,包括增长减缓,细胞死亡和分化,而不会影响正常的骨髓细胞.
这两种化合物在AML模型中都显示出强大的体内疗效,诱导单细胞分化并减少白血病负担.
DB1055有效地减少了患者衍生异体移植中的白血病负担,验证了其治疗潜力.

结论:

抑制HOXA9 / DNA与DB1055和DB818等DNA配体的相互作用代表了AML的新治疗方法.
这一策略可以克服化学抵抗并改善HOXA9依赖的AML患者的治疗结果.
DB1055和DB818作为AML的新差异化疗法具有前景.

更多相关视频

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

Co-Culture and Transduction of Murine Thymocytes on Delta-Like 4-Expressing Stromal Cells to Study Oncogenes in T-Cell Leukemia

Co-Culture and Transduction of Murine Thymocytes on Delta-Like 4-Expressing Stromal Cells to Study Oncogenes in T-Cell Leukemia

Published on: June 9, 2023

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...